These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23470466)

  • 1. Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.
    Yoshimura K; Minami T; Nozawa M; Uemura H
    Br J Cancer; 2013 Apr; 108(6):1260-6. PubMed ID: 23470466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
    Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
    Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
    Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
    Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
    Terakawa T; Miyake H; Kusuda Y; Fujisawa M
    Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical study of brain metastasis of renal cell carcinoma.
    Harada Y; Nonomura N; Kondo M; Nishimura K; Takahara S; Miki T; Okuyama A
    Eur Urol; 1999 Sep; 36(3):230-5. PubMed ID: 10450008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting.
    May M; Brookman-May S; Hoschke B; Gilfrich C; Kendel F; Baxmann S; Wittke S; Kiessig ST; Miller K; Johannsen M
    Cancer Immunol Immunother; 2010 May; 59(5):687-95. PubMed ID: 19876628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.
    Tani K; Azuma M; Nakazaki Y; Oyaizu N; Hase H; Ohata J; Takahashi K; OiwaMonna M; Hanazawa K; Wakumoto Y; Kawai K; Noguchi M; Soda Y; Kunisaki R; Watari K; Takahashi S; Machida U; Satoh N; Tojo A; Maekawa T; Eriguchi M; Tomikawa S; Tahara H; Inoue Y; Yoshikawa H; Yamada Y; Iwamoto A; Hamada H; Yamashita N; Okumura K; Kakizoe T; Akaza H; Fujime M; Clift S; Ando D; Mulligan R; Asano S
    Mol Ther; 2004 Oct; 10(4):799-816. PubMed ID: 15451464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.
    Vrdoljak E; Géczi L; Mardiak J; Ciuleanu TE; Leyman S; Zhang K; Sajben P; Torday L
    Pathol Oncol Res; 2015 Jul; 21(3):775-82. PubMed ID: 25557271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.
    Obara W; Karashima T; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Inoue K; Katagiri T; Shuin T; Nakamura Y; Fujioka T
    Cancer Immunol Immunother; 2017 Jan; 66(1):17-24. PubMed ID: 27757561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma.
    Steiner T; Kirchner H; Siebels M; Doehn C; Heynemann H; Varga Z; Rohde D; Schubert J; Jocham D; Stief C; Fornara P; Hofmann R; Loening S; Roigas J
    J Cancer Res Clin Oncol; 2010 Jun; 136(6):905-10. PubMed ID: 20012752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
    Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
    Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
    Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
    Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
    Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
    Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
    Oudard S; Rixe O; Beuselinck B; Linassier C; Banu E; Machiels JP; Baudard M; Ringeisen F; Velu T; Lefrere-Belda MA; Limacher JM; Fridman WH; Azizi M; Acres B; Tartour E
    Cancer Immunol Immunother; 2011 Feb; 60(2):261-71. PubMed ID: 21069322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
    Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
    Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma.
    Kis B; Shah J; Choi J; El-Haddad G; Sweeney J; Biebel B; Mellon E; Frakes JM; Hoffe SE; Fishman MN; Shridhar R
    J Vasc Interv Radiol; 2017 Feb; 28(2):254-259. PubMed ID: 27955832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailor-made renal cell carcinoma vaccines.
    Dranoff G
    Cancer Cell; 2012 Sep; 22(3):287-9. PubMed ID: 22975372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.